Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Gilead Letairis Will Be Available Through LEAP Restricted Distribution Program

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Ambrisentan beats out Encysive's Thelin in race for FDA approval for treatment of pulmonary arterial hypertension.

You may also be interested in...



Gilead Grabs Cicletanine For PAH From Navitas

Bargain-priced drug has orphan status pending, could complement Letairis.

Gilead Grabs Cicletanine For PAH From Navitas

Bargain-priced drug has orphan status pending, could complement Letairis.

Actelion Vows To Keep PAH Lead, Despite First-Quarter Dip

Swiss firm blames currency fluctuations and buying patterns for Tracleer and Ventavis sales reductions.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Pharming’s Joenja, Cidara’s Rezzayo And Incyte’s Zynyz Headline US FDA Approval Bonanza

House QALY Bill Overreach Threatens Medicare Price Negotiation Program, Democrats Warn

Recent And Upcoming FDA Advisory Committee Meetings

iPLEDGE REMS: FDA Panel To Consider Changing Pregnancy Testing, Counseling Requirements

See All
UsernamePublicRestriction

Register

PS066185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By